Adverse event reporting encompasses all systematic processes for the collection, assessment, documentation, and reporting of adverse events in clinical trials. These reporting obligations are precisely defined in international guidelines such as ICH-GCP E6 and regulatory requirements from the EMA, FDA, and national authorities. Expedited reporting of suspected unexpected serious adverse reactions (SUSARs) must adhere to strict deadlines: 7 days for life-threatening events and 15 days for other serious events.
CROs implement robust pharmacovigilance systems with 24/7 availability for AE reports from investigational sites. Modern safety platforms automate case processing, expectedness assessment, and regulatory reporting. Medical coding according to MedDRA standards, causality assessment based on WHO-Uppsala criteria, and the automated generation of CIOMS reports are integral components of these systems.
The quality of reporting directly influences patient safety and regulatory compliance. Training programs for investigational sites on correct AE collection, quality assurance processes for incoming safety data, and proactive signal detection through statistical methods are essential. Risk-based monitoring increasingly focuses on the quality of safety data, while regulatory intelligence systems continuously monitor the evolving safety requirements of various authorities.